RCAP
PCVX icon

Resolute Capital Asset Partners’s Vaxcyte PCVX Stock Holding History

Resolute Capital Asset Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,000
Closed -$2.5M – 42
2023
Q2 		$2.5M Buy
+50,000
New +$2.37M 1.78% 24

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Resolute Capital Asset Partners's PCVX Position: Q3 2023 in Review

Resolute Capital Asset Partners sold out of Vaxcyte (PCVX) in Q3 2023, closing a stake of 50,000 shares — an estimated $2.5M sold.

Resolute Capital Asset Partners first reported a position in PCVX in Q2 2023 and held it in 1 quarter. The position peaked at $2.5M in Q2 2023. 202 funds tracked by Wall St. Rank hold PCVX as of Q3 2023.

  • Resolute Capital Asset Partners reported no remaining Vaxcyte position as of Q3 2023 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 50,000 Vaxcyte shares in Q3 2023, an estimated $2.5M.
  • Resolute Capital Asset Partners first reported a position in Vaxcyte in Q2 2023 and held it in 1 quarter.
  • Resolute Capital Asset Partners's Vaxcyte position peaked at $2.5M in Q2 2023.
  • 202 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2023.

Based on Resolute Capital Asset Partners's 13F filing for Q3 2023, filed 13 Nov 2023.